Related Experiment Video

Updated: Aug 30, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer

Dean A Fennell1

  • 1Lung Cancer Section, Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom. d.a.fennell@qmul.ac.uk

Clinical Lung Cancer
|November 12, 2003
PubMed

Insights

Small-cell lung cancer (SCLC) often becomes resistant to chemotherapy due to Bcl-2 protein overexpression, leading to poor outcomes. Targeting Bcl-2 with gene silencing offers a promising strategy to overcome this resistance and improve patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Small-cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis, often presenting as metastatic disease.
  • Acquisition of apoptosis resistance is a common mechanism of treatment failure in SCLC following initial therapy.
  • Overexpression of the anti-apoptosis protein Bcl-2 is prevalent in SCLC and contributes significantly to chemoresistance.

Purpose of the Study:

  • To discuss the role of Bcl-2 in apoptosis resistance in SCLC.
  • To explore the potential of targeting Bcl-2 as a therapeutic strategy for SCLC.
  • To investigate the use of gene silencing to overcome Bcl-2-mediated chemoresistance.

Main Methods:

  • Review of in vitro and in vivo evidence regarding Bcl-2 function in SCLC.
  • Discussion of the mechanisms by which Bcl-2 contributes to apoptosis resistance.
  • Exploration of gene silencing techniques for targeting Bcl-2.

Main Results:

  • Evidence supports Bcl-2 overexpression as a key factor in SCLC apoptosis resistance.
  • Targeting Bcl-2 presents a novel therapeutic avenue for overcoming chemoresistance.
  • Gene silencing strategies show potential for clinical application in SCLC.

Conclusions:

  • Bcl-2 plays a critical role in SCLC chemoresistance by inhibiting apoptosis.
  • Targeting Bcl-2, particularly through gene silencing, is a promising strategy to improve treatment outcomes in SCLC.
  • Further research into Bcl-2 targeted therapies is warranted for SCLC patients.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...